Skip to main content
Top
Published in: Tumor Biology 9/2016

Open Access 01-09-2016 | Original Article

Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin

Authors: Bo Chen, Qi-Cong Luo, Jian-Bo Chen, Li-E Lin, Ming-Xu Luo, Hong-Yue Ren, Pei-Qiong Chen, Lian-Guo Shi

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

Cell plasma membrane proteins, playing a crucial role in cell malignant transformation and development, were the main targets of tumor detection and therapy. In this study, CyDye/biotin double-labeling proteomic approach was adopted to profile the membrane proteome of gastric cancer cell line BGC-823 and paired immortalized gastric epithelial cell GES-1. Real-time PCR, Western blotting, and immunohistochemical staining were used to validate the differential expression of a novel identified cell surface marker R-cadherin in gastric cancer cells and tissues. Clinicopathological study and survival analysis were performed to estimate its roles in tumor progression and outcome prediction. Real-time PCR and Western blotting showed that the expression level of R-cadherin in gastric cancer were significantly lower than non-cancerous epithelial cell and tissues. Clinicopathological study indicated that R-cadherin was dominantly expressed on cell surface of normal gastric epithelium, and its expression deletion in gastric cancer tissues was associated with tumor site, differentiation, lymph node metastasis, and pTNM (chi-square test, P < 0.05). Those patients with R-cadherin positive expression displayed better overall survivals than negative expression group (log-rank test, P = 0.000). Cox multivariate survival analysis revealed lacking the expression of R-cadherin was a main independent predictor for poor clinical outcome in gastric cancer (RR = 5.680, 95 % CI 2.250–14.341, P < 0.01). We have established a fundamental membrane proteome database for gastric cancer and identified R-cadherin as a tumor differentiation and progression-related cell surface marker of gastric cancer. Lacking the expression of R-cadherin indicates poor prognosis in patients with gastric cancer.
Literature
1.
go back to reference Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4:156–69.CrossRefPubMedPubMedCentral Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4:156–69.CrossRefPubMedPubMedCentral
2.
go back to reference Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–60.CrossRefPubMed Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250–60.CrossRefPubMed
3.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
4.
go back to reference Shen L, Shan YS, Hu HM, Price TJ, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.CrossRefPubMed Shen L, Shan YS, Hu HM, Price TJ, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535–47.CrossRefPubMed
5.
go back to reference Sung JJ, Ng EK, Lin JT, Ho KY, et al. Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011. J Gastroenterol Hepatol. 2012;27:1417–22.CrossRefPubMed Sung JJ, Ng EK, Lin JT, Ho KY, et al. Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011. J Gastroenterol Hepatol. 2012;27:1417–22.CrossRefPubMed
6.
go back to reference Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48–63.CrossRef Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48–63.CrossRef
7.
go back to reference Leung WK, Wu MS, Kakugawa Y, Kim JJ, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.CrossRefPubMed Leung WK, Wu MS, Kakugawa Y, Kim JJ, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.CrossRefPubMed
8.
go back to reference Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (review). Oncol Lett. 2015;9:1502–8.PubMedPubMedCentral Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early diagnosis and prognosis (review). Oncol Lett. 2015;9:1502–8.PubMedPubMedCentral
9.
go back to reference Pinheiro Ddo R, Ferreira WA, Barros MB, Araujo MD, et al. Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications. World J Gastroenterol. 2014;20:11574–85.CrossRefPubMed Pinheiro Ddo R, Ferreira WA, Barros MB, Araujo MD, et al. Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications. World J Gastroenterol. 2014;20:11574–85.CrossRefPubMed
10.
go back to reference De Vita F, Di Martino N, Fabozzi A, Laterza MM, et al. Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol. 2014;20:14537–58.CrossRefPubMedPubMedCentral De Vita F, Di Martino N, Fabozzi A, Laterza MM, et al. Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol. 2014;20:14537–58.CrossRefPubMedPubMedCentral
11.
go back to reference Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 1846;2014:232–7. Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta. 1846;2014:232–7.
12.
go back to reference Aprile G, Giampieri R, Bonotto M, Bittoni A, et al. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs. 2014;23:925–42.CrossRefPubMed Aprile G, Giampieri R, Bonotto M, Bittoni A, et al. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs. 2014;23:925–42.CrossRefPubMed
13.
go back to reference Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol. 2012;13:377–89.CrossRefPubMed Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol. 2012;13:377–89.CrossRefPubMed
15.
go back to reference De Mattos-Arruda L, Olmos D, Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol. 2011;7:1385–97.CrossRefPubMed De Mattos-Arruda L, Olmos D, Tabernero J. Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol. 2011;7:1385–97.CrossRefPubMed
16.
go back to reference Okabe H, Tsunoda S, Hosogi H, Hisamori S, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22:3954–61.CrossRefPubMed Okabe H, Tsunoda S, Hosogi H, Hisamori S, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22:3954–61.CrossRefPubMed
17.
go back to reference Zhang ZY, Dai ZL, Yin XW, Li SH, et al. Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer. BMC Cancer. 2014;14:773.CrossRefPubMedPubMedCentral Zhang ZY, Dai ZL, Yin XW, Li SH, et al. Meta-analysis shows that circulating tumor cells including circulating microRNAs are useful to predict the survival of patients with gastric cancer. BMC Cancer. 2014;14:773.CrossRefPubMedPubMedCentral
18.
go back to reference Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199–215.CrossRefPubMed Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199–215.CrossRefPubMed
19.
go back to reference Satelli A, Brownlee Z, Mitra A, Meng QH, et al. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61:259–66.CrossRefPubMed Satelli A, Brownlee Z, Mitra A, Meng QH, et al. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61:259–66.CrossRefPubMed
20.
21.
go back to reference Liu CH, Tang WC, Sia P, Huang CC, et al. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (emt)-associated genes with predictive and prognostic relevance. Int J Med Sci. 2015;12:63–71.CrossRefPubMedPubMedCentral Liu CH, Tang WC, Sia P, Huang CC, et al. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (emt)-associated genes with predictive and prognostic relevance. Int J Med Sci. 2015;12:63–71.CrossRefPubMedPubMedCentral
22.
go back to reference Leth-Larsen R, Lund RR, Ditzel HJ. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics. 2010;9:1369–82.CrossRefPubMedPubMedCentral Leth-Larsen R, Lund RR, Ditzel HJ. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics. 2010;9:1369–82.CrossRefPubMedPubMedCentral
23.
go back to reference Mermelekas G, Zoidakis J. Mass spectrometry-based membrane proteomics in cancer biomarker discovery. Expert Rev Mol Diagn. 2014;14:549–63.CrossRefPubMed Mermelekas G, Zoidakis J. Mass spectrometry-based membrane proteomics in cancer biomarker discovery. Expert Rev Mol Diagn. 2014;14:549–63.CrossRefPubMed
24.
go back to reference Lund R, Leth-Larsen R, Jensen ON, Ditzel HJ. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J Proteome Res. 2009;8:3078–90.CrossRefPubMed Lund R, Leth-Larsen R, Jensen ON, Ditzel HJ. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J Proteome Res. 2009;8:3078–90.CrossRefPubMed
25.
go back to reference Gao W, Xu J, Wang F, Zhang L, et al. Plasma membrane proteomic analysis of human gastric cancer tissues: revealing flotillin 1 as a marker for gastric cancer. BMC Cancer. 2015;15:367.CrossRefPubMedPubMedCentral Gao W, Xu J, Wang F, Zhang L, et al. Plasma membrane proteomic analysis of human gastric cancer tissues: revealing flotillin 1 as a marker for gastric cancer. BMC Cancer. 2015;15:367.CrossRefPubMedPubMedCentral
26.
go back to reference Sidibe A, Yin X, Tarelli E, Xiao Q, et al. Integrated membrane protein analysis of mature and embryonic stem cell-derived smooth muscle cells using a novel combination of cydye/biotin labeling. Mol Cell Proteomics. 2007;6:1788–97.CrossRefPubMed Sidibe A, Yin X, Tarelli E, Xiao Q, et al. Integrated membrane protein analysis of mature and embryonic stem cell-derived smooth muscle cells using a novel combination of cydye/biotin labeling. Mol Cell Proteomics. 2007;6:1788–97.CrossRefPubMed
27.
go back to reference Shukla HD, Vaitiekunas P, Cotter RJ. Advances in membrane proteomics and cancer biomarker discovery: current status and future perspective. Proteomics. 2012;12:3085–104.CrossRefPubMed Shukla HD, Vaitiekunas P, Cotter RJ. Advances in membrane proteomics and cancer biomarker discovery: current status and future perspective. Proteomics. 2012;12:3085–104.CrossRefPubMed
28.
go back to reference Nunomura K, Nagano K, Itagaki C, Taoka M, et al. Cell surface labeling and mass spectrometry reveal diversity of cell surface markers and signaling molecules expressed in undifferentiated mouse embryonic stem cells. Mol Cell Proteomics. 2005;4:1968–76.CrossRefPubMed Nunomura K, Nagano K, Itagaki C, Taoka M, et al. Cell surface labeling and mass spectrometry reveal diversity of cell surface markers and signaling molecules expressed in undifferentiated mouse embryonic stem cells. Mol Cell Proteomics. 2005;4:1968–76.CrossRefPubMed
29.
go back to reference Paredes J, Figueiredo J, Albergaria A, Oliveira P, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 1826;2012:297–311. Paredes J, Figueiredo J, Albergaria A, Oliveira P, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 1826;2012:297–311.
31.
go back to reference Kim SA, Inamura K, Yamauchi M, Nishihara R, et al. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer. 2016;114:199–206.CrossRefPubMed Kim SA, Inamura K, Yamauchi M, Nishihara R, et al. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer. 2016;114:199–206.CrossRefPubMed
32.
go back to reference van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14:121–34.CrossRefPubMed van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14:121–34.CrossRefPubMed
33.
go back to reference Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731.CrossRefPubMedPubMedCentral Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731.CrossRefPubMedPubMedCentral
34.
go back to reference Vedula SR, Lim TS, Hunziker W, Lim CT. Mechanistic insights into the physiological functions of cell adhesion proteins using single molecule force spectroscopy. Mol Cell Biomech. 2008;5:169–82.PubMed Vedula SR, Lim TS, Hunziker W, Lim CT. Mechanistic insights into the physiological functions of cell adhesion proteins using single molecule force spectroscopy. Mol Cell Biomech. 2008;5:169–82.PubMed
35.
go back to reference Inuzuka H, Miyatani S, Takeichi M. R-cadherin: a novel Ca(2+)-dependent cell-cell adhesion molecule expressed in the retina. Neuron. 1991;7:69–79.CrossRefPubMed Inuzuka H, Miyatani S, Takeichi M. R-cadherin: a novel Ca(2+)-dependent cell-cell adhesion molecule expressed in the retina. Neuron. 1991;7:69–79.CrossRefPubMed
36.
go back to reference Miotto E, Sabbioni S, Veronese A, Calin GA, et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res. 2004;64:8156–9.CrossRefPubMed Miotto E, Sabbioni S, Veronese A, Calin GA, et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res. 2004;64:8156–9.CrossRefPubMed
37.
go back to reference Kucharczak J, Charrasse S, Comunale F, Zappulla J, et al. R-cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res. 2008;68:6559–68.CrossRefPubMed Kucharczak J, Charrasse S, Comunale F, Zappulla J, et al. R-cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res. 2008;68:6559–68.CrossRefPubMed
38.
go back to reference Du C, Huang T, Sun D, Mo Y, et al. CDH4 as a novel putative tumor suppressor gene epigenetically silenced by promoter hypermethylation in nasopharyngeal carcinoma. Cancer Lett. 2011;309:54–61.CrossRefPubMed Du C, Huang T, Sun D, Mo Y, et al. CDH4 as a novel putative tumor suppressor gene epigenetically silenced by promoter hypermethylation in nasopharyngeal carcinoma. Cancer Lett. 2011;309:54–61.CrossRefPubMed
39.
go back to reference Nishioka Y, Ueki T, Hokazono K, Nagayoshi K, et al. Comparative detection of aberrantly methylated DNA in preoperative and postoperative stool from patients with colorectal cancers. Int J Biol Markers. 2015;30:e81–7.CrossRefPubMed Nishioka Y, Ueki T, Hokazono K, Nagayoshi K, et al. Comparative detection of aberrantly methylated DNA in preoperative and postoperative stool from patients with colorectal cancers. Int J Biol Markers. 2015;30:e81–7.CrossRefPubMed
40.
go back to reference Tani N, Ichikawa D, Ikoma D, Ikoma H, et al. An early detection of recurrence using reverse transcriptase-polymerase chain reaction (rt-pcr) and methylation-specific polymerase chain reaction (msp) from peripheral blood in patients after gastrectomy. Gan To Kagaku Ryoho. 2006;33:1720–2.PubMed Tani N, Ichikawa D, Ikoma D, Ikoma H, et al. An early detection of recurrence using reverse transcriptase-polymerase chain reaction (rt-pcr) and methylation-specific polymerase chain reaction (msp) from peripheral blood in patients after gastrectomy. Gan To Kagaku Ryoho. 2006;33:1720–2.PubMed
41.
go back to reference Agiostratidou G, Li M, Suyama K, Badano I, et al. Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res. 2009;69:5030–8.CrossRefPubMedPubMedCentral Agiostratidou G, Li M, Suyama K, Badano I, et al. Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res. 2009;69:5030–8.CrossRefPubMedPubMedCentral
42.
go back to reference Cosgrove D, Zallocchi M. Usher protein functions in hair cells and photoreceptors. Int J Biochem Cell Biol. 2014;46:80–9.CrossRefPubMed Cosgrove D, Zallocchi M. Usher protein functions in hair cells and photoreceptors. Int J Biochem Cell Biol. 2014;46:80–9.CrossRefPubMed
43.
go back to reference Webb SW, Grillet N, Andrade LR, Xiong W, et al. Regulation of PCDH15 function in mechanosensory hair cells by alternative splicing of the cytoplasmic domain. Development. 2011;138:1607–17.CrossRefPubMedPubMedCentral Webb SW, Grillet N, Andrade LR, Xiong W, et al. Regulation of PCDH15 function in mechanosensory hair cells by alternative splicing of the cytoplasmic domain. Development. 2011;138:1607–17.CrossRefPubMedPubMedCentral
44.
go back to reference Rouget-Quermalet V, Giustiniani J, Marie-Cardine A, Beaud G, et al. Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas. Oncogene. 2006;25:2807–11.CrossRefPubMed Rouget-Quermalet V, Giustiniani J, Marie-Cardine A, Beaud G, et al. Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas. Oncogene. 2006;25:2807–11.CrossRefPubMed
45.
go back to reference Berezowska S, Novotny A, Bauer K, Feuchtinger A, et al. Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PLoS One. 2013;8, e69098.CrossRefPubMedPubMedCentral Berezowska S, Novotny A, Bauer K, Feuchtinger A, et al. Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PLoS One. 2013;8, e69098.CrossRefPubMedPubMedCentral
46.
go back to reference Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, et al. Heat shock protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC Gastroenterol. 2009;9:14.CrossRefPubMedPubMedCentral Giaginis C, Daskalopoulou SS, Vgenopoulou S, Sfiniadakis I, et al. Heat shock protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival. BMC Gastroenterol. 2009;9:14.CrossRefPubMedPubMedCentral
47.
go back to reference Wu W, Juan WC, Liang CR, Yeoh KG, et al. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl. 2012;6:152–62.CrossRefPubMed Wu W, Juan WC, Liang CR, Yeoh KG, et al. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. Proteomics Clin Appl. 2012;6:152–62.CrossRefPubMed
Metadata
Title
Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin
Authors
Bo Chen
Qi-Cong Luo
Jian-Bo Chen
Li-E Lin
Ming-Xu Luo
Hong-Yue Ren
Pei-Qiong Chen
Lian-Guo Shi
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5032-z

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine